Journal
SMALL
Volume 18, Issue 49, Pages -Publisher
WILEY-V C H VERLAG GMBH
DOI: 10.1002/smll.202205193
Keywords
anticancer vaccines; immunotherapy; MnO; (2); polythiophene; tumor cell membranes
Categories
Funding
- National Natural Science Foundation of China [22135005, 52131302, 21721005, 51833007]
Ask authors/readers for more resources
This study presents a hybrid nanovaccine that can enhance T-cell immune responses by promoting antigen presentation and achieve effective cancer therapy through near-infrared light activation.
Although anticancer vaccines have achieved certain effects in early clinical practice, T cell immunity as the most common responsive pattern of anticancer vaccines is still limited by unsatisfied tumor recognition and inhibition efficiency. As the critical step of T cell immunity, uptake and presentation of specific antigen by antigen-presenting cells (APC) can be activated by inflammation for enhancing the response of T cells to the antigen source. Here, a hybrid nanovaccine named PTh/MnO2@M activated with a near-infrared ray (NIR) is prepared by coating an autologous tumor cell membrane on the surface of a polythiophene/MnO2 composite core. The photoelectrical material polythiophene can produce local microinflammation under NIR radiation and activate specific T cell antitumor immunity by promoting APC maturation and autologous tumor antigens presentation. Moreover, the synthesized nanovaccine PTh/MnO2@M is shown to induce a significant antitumor immune response, effectively inhibit the progression of melanoma in mice, and significantly prolong the survival time of mice in vivo. This strategy aims to enhance T-cell immune responses by promoting antigen presentation, leading to effective and specific cancer therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available